Equities analysts predict that Insulet Co. (NASDAQ:PODD) will post earnings of ($0.15) per share for the current quarter, Zacks reports. Ten analysts have issued estimates for Insulet’s earnings, with the lowest EPS estimate coming in at ($0.23) and the highest estimate coming in at ($0.03). Insulet reported earnings of ($0.19) per share during the same quarter last year, which indicates a positive year over year growth rate of 21.1%. The firm is scheduled to issue its next earnings report after the market closes on Monday, May 8th.
According to Zacks, analysts expect that Insulet will report full year earnings of ($0.41) per share for the current year, with EPS estimates ranging from ($0.60) to $0.00. For the next year, analysts anticipate that the company will post earnings of ($0.07) per share, with EPS estimates ranging from ($0.45) to $0.19. Zacks’ EPS calculations are an average based on a survey of sell-side research firms that that provide coverage for Insulet.
Insulet (NASDAQ:PODD) last announced its quarterly earnings results on Monday, February 27th. The medical instruments supplier reported ($0.16) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.05) by $0.11. The company earned $103.58 million during the quarter, compared to the consensus estimate of $100.61 million. Insulet had a negative net margin of 12.95% and a negative return on equity of 87.46%. The business’s revenue was up 23.6% on a year-over-year basis. During the same quarter in the prior year, the firm posted ($0.48) earnings per share.
A number of equities analysts have recently commented on the stock. B. Riley reaffirmed a “neutral” rating and issued a $44.00 target price on shares of Insulet in a report on Wednesday, March 1st. Oppenheimer Holdings Inc. set a $46.00 target price on shares of Insulet and gave the company a “hold” rating in a report on Tuesday, February 28th. Jefferies Group LLC reaffirmed a “buy” rating and issued a $53.00 target price on shares of Insulet in a report on Thursday, April 13th. Canaccord Genuity reaffirmed a “hold” rating and issued a $39.00 target price on shares of Insulet in a report on Monday, February 13th. Finally, Zacks Investment Research raised shares of Insulet from a “hold” rating to a “buy” rating and set a $42.00 price objective on the stock in a research note on Tuesday, January 10th. One investment analyst has rated the stock with a sell rating, seven have given a hold rating and six have issued a buy rating to the stock. The stock presently has a consensus rating of “Hold” and a consensus price target of $45.73.
Shares of Insulet (NASDAQ:PODD) traded up 1.19% during mid-day trading on Thursday, reaching $41.80. 250,614 shares of the company’s stock were exchanged. Insulet has a 1-year low of $26.50 and a 1-year high of $48.23. The stock’s market capitalization is $2.41 billion. The company’s 50 day moving average is $43.35 and its 200 day moving average is $40.22.
In other Insulet news, Director David A. Lemoine sold 1,282 shares of the business’s stock in a transaction on Monday, March 6th. The shares were sold at an average price of $45.15, for a total transaction of $57,882.30. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director Joseph S. Zakrzewski sold 40,000 shares of the business’s stock in a transaction on Thursday, March 2nd. The stock was sold at an average price of $46.86, for a total transaction of $1,874,400.00. The disclosure for this sale can be found here. Insiders have sold a total of 81,282 shares of company stock worth $3,732,282 over the last 90 days. Insiders own 1.90% of the company’s stock.
Several large investors have recently modified their holdings of PODD. WFG Advisors LP bought a new stake in shares of Insulet during the fourth quarter valued at approximately $141,000. Cantab Capital Partners LLP bought a new stake in shares of Insulet during the fourth quarter valued at approximately $143,000. Pacad Investment Ltd. raised its stake in shares of Insulet by 85.7% in the fourth quarter. Pacad Investment Ltd. now owns 5,200 shares of the medical instruments supplier’s stock valued at $196,000 after buying an additional 2,400 shares during the last quarter. SG Americas Securities LLC bought a new stake in shares of Insulet during the third quarter valued at approximately $243,000. Finally, BNP Paribas Arbitrage SA raised its stake in shares of Insulet by 75.8% in the third quarter. BNP Paribas Arbitrage SA now owns 6,487 shares of the medical instruments supplier’s stock valued at $266,000 after buying an additional 2,796 shares during the last quarter.
Insulet Company Profile
Insulet Corporation is engaged in the development, manufacturing and sale of the OmniPod Insulin Management System (the OmniPod System), an insulin delivery system for people with insulin-dependent diabetes. The Omnipod System features a self-adhesive disposable tubeless Omnipod device, which is worn on the body for approximately three days at a time and its wireless companion, the handheld Personal Diabetes Manager (PDM).
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Insulet Co. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Insulet Co. and related companies with MarketBeat.com's FREE daily email newsletter.